Overview of the use of CoQ10 in cardiovascular disease.
The clinical experience in cardiology with CoQ10 includes studies on congestive heart failure, ischemic heart disease, hypertensive heart disease, diastolic dysfunction of the left ventricle, and reperfusion injury as it relates to coronary artery bypass graft surgery. The CoQ10-lowering effect of HMG-CoA reductase inhibitors and the potential adverse consequences are of growing concern. Supplemental CoQ10 alters the natural history of cardiovascular illnesses and has the potential for prevention of cardiovascular disease through the inhibition of LDL cholesterol oxidation and by the maintenance of optimal cellular and mitochondrial function throughout the ravages of time and internal and external stresses. The attainment of higher blood levels of CoQ10 (> 3.5 micrograms/ml) with the use of higher doses of CoQ10 appears to enhance both the magnitude and rate of clinical improvement. In this communication, 34 controlled trials and several open-label and long-term studies on the clinical effects of CoQ10 in cardiovascular diseases are reviewed.
P H
PH
Langsjoen
A M
AM
Langsjoen
D000975:Antioxidants / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003067:Coenzymes; D001026:Coronary Artery Bypass; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D017202:Myocardial Ischemia / Q000188:drug therapy; D015427:Reperfusion Injury / Q000188:drug therapy; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy
D000975:Antioxidants; D003067:Coenzymes; D014451:Ubiquinone; C024989:coenzyme Q10